Use of recombinant allergens and antigens in clinical diagnosis (Q12379): Difference between revisions
Jump to navigation
Jump to search
(Created claim: summary (P836): The subject of the project is industrial research and experimental development focused on the field of in vitro diagnostics, namely the use of recombinant allergens and antigens in the form of prototypes of BAT tests and ELISA kits for qualitative diagnostics and monitoring of therapy of allergological reactions of patients and selected bacterial infections. The resulting high-tech products will match the parameters of the world’s top, or excee...) |
(Changed label, description and/or aliases in 2 languages: Changing unique label-description pair) |
||
| description / en | description / en | ||
Project in Czech Republic | Project Q12379 in Czech Republic | ||
| description / cs | description / cs | ||
Projekt v | Projekt Q12379 v Czechia | ||
Revision as of 15:56, 28 October 2020
Project Q12379 in Czech Republic
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Use of recombinant allergens and antigens in clinical diagnosis |
Project Q12379 in Czech Republic |
Statements
15,323,532.49 Czech koruna
0 references
24,835,547.0 Czech koruna
0 references
61.7 percent
0 references
30 June 2022
0 references
EXBIO Praha, a.s.
0 references
49°59'0.49"N, 14°30'9.11"E
0 references
25250
0 references
Předmětem projektu je průmyslový výzkum a experimentální vývoj zaměřený na oblast diagnostik in vitro, konkrétně na využití rekombinantních alergenů a antigenů v podobě prototypů BAT testů a ELISA souprav pro kvalitativní diagnostiku a monitoring terapie alergologických reakcí pacientů a vybraných bakteriálních infekcí. Výsledné high-tech produkty se vyrovnají parametrům světové špičky, resp. překračují technické parametry známých řešení a budou uvedeny na evropský a světový trh. a. (Czech)
0 references
The subject of the project is industrial research and experimental development focused on the field of in vitro diagnostics, namely the use of recombinant allergens and antigens in the form of prototypes of BAT tests and ELISA kits for qualitative diagnostics and monitoring of therapy of allergological reactions of patients and selected bacterial infections. The resulting high-tech products will match the parameters of the world’s top, or exceed the technical parameters of known solutions and will be introduced to the European and world market. a. (English)
22 October 2020
0 references
Identifiers
CZ.01.1.02/0.0/0.0/17_176/0015521
0 references